Lennox-Gastaut Syndrome Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent and Other Developments

Lennox-Gastaut Syndrome is a rare form of epilepsy that occurs in childhood and is characterized by seizures and intellectual disability. Adverse conditions such as injury to brain and its malformation, lack of oxygen to the new-born infants, infections of central nervous system and inherited metabolic or degenerative disorders are responsible for occurrence of Lennox-Gastaut Syndrome. Anti-epileptic medications are the main treatment option for Lennox-Gastaut Syndrome. The medication is often complicated in case of paediatric disorders as there is risk in development of new-born, due to which various research organizations are focussing on development of therapeutics of Lennox-Gastaut Syndrome.

Explore Report at: www.psmarketresearch.com/market-analysis/lennox-gastaut-syndrome-therapeutics-pipeline-analysis

The growth in therapeutic pipeline of Lennox-Gastaut Syndrome can also be attributed to the upsurge in technical advancements in research, increase in funding by non-profit organization such as National Organization for Rare Disorders as well as availability of limited number of treatments.

In August 2017, INSYS Therapeutics Inc. started a Phase III study of an oral solution of cannabidiol, to assess its safety and efficacy as an adjunctive therapy for treatment in subjects with uncontrolled Lennox-Gastaut Syndrome. The trial is expected to be completed in June 2018. In December 2016, Eisai Inc. conducted a Phase III study on its drug candidate, perampanel, for reducing the drop seizures in patients with uncontrolled seizures and Lennox-Gastaut Syndrome. The trial is expected to be completed in February 2020. In January 2016, Zogenix, Inc. started a Phase II clinical study of its drug candidate, fenfluramine, in subjects having epilepsy and Lennox Gastaut Syndrome. The purpose of the study was to evaluate the anti-epileptic effects of low dose fenfluramine in these patients. The trial was expected to be completed in March 2017, however, the study is still ongoing and recruiting participants. In June 2011, Eisai Inc. strated a Phase III study of drug candidate, rufinamide, to evaluate its safety, efficacy and pharmacokinetic activity in subjects of less than four years of age and having uncontrolled Lennox-Gastaut Syndrome. The trial was completed in November 2015.

Request for Table of Content at: www.psmarketresearch.com/market-analysis/lennox-gastaut-syndrome-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of Lennox-Gastaut Syndrome therapeutics include, INSYS Therapeutics Inc., Eisai Inc., GW Research Ltd., Zogenix, Inc., Johnson & Johnson Pharmaceutical Research & Development, LLC, H. Lundbeck A/S, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Ortho-McNeil Pharmaceutical Ltd.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Kundan
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.